Company / Cash & Equivalents
Co-Diagnostics, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$11.9M
FY2025
5-year range
$2.9M / $88.6M
FY2021-FY2025
Trend
+304.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +305% YoY in FY2025, a notable deviation from the 8-year average annual change of +639%.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of -22.7%.
Declined from $15M to $12M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -19.7%
- 5-Year CAGR
- -22.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -22.7%, indicating a declining trend.
- In FY2025, cash & equivalents increased 304.7% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.9M | +304.7% |
| FY2024 | $2.9M | -80.3% |
| FY2023 | $14.9M | -35.1% |
| FY2022 | $23.0M | -74.1% |
| FY2021 | $88.6M | +106.2% |
| FY2020 | $43.0M | +4711.9% |
| FY2019 | $893.1K | -74.7% |
| FY2018 | $3.5M | +253.9% |
| FY2017 | $998.7K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026